Summary
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRα, β and γ) developed at Saint Louis University. In mice it raised endurance capacity and fat oxidation, which led researchers to describe it as an exercise mimetic.
How it works
ERRα and ERRγ regulate genes for mitochondrial biogenesis and oxidative metabolism in muscle. Activating them shifts muscle toward a more oxidative, fatigue-resistant profile.
Research use cases
Areas where SLU-PP-332 has been studied. Inclusion here does not mean it works for that purpose.
- Skeletal muscle oxidative capacity
- Obesity and metabolic syndrome models
What the research found
Exercise capacity
Treated mice ran about 70% longer and 45% farther than controls, with more oxidative muscle fibres.1
Obesity models
In obese mice, SLU-PP-332 reduced fat mass and improved insulin sensitivity without changing food intake.2
Safety and open questions
No human safety or pharmacokinetic data exist.
Regulatory status
Preclinical. No human studies. Sold for research use.
Status was accurate when this page was last reviewed on October 26, 2026. Regulations change; check with the relevant authority before relying on it.
SLU-PP-332: common questions
Is SLU-PP-332 an estrogen?
No. Despite the name, estrogen-related receptors do not bind estrogen. They are orphan nuclear receptors that regulate energy metabolism.
Is SLU-PP-332 approved for human use?
Preclinical. No human studies. Sold for research use.
References
- Billon C, Sitaula S, Banerjee S, et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology.
- Billon C, Schoepke E, Avdagic A, et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics.
Links open a PubMed search for the exact title, or the original source where one is given.